Figure 5.

Treatment algorithm for stage IV mNSCLC with BRAF V600 mutation. Purple: general categories or stratification; blue: systemic anticancer therapy; turquoise: combination of treatments or other systemic treatments; white: other aspects of management. ChT, chemotherapy, CPG, Clinical Practice Guideline; EMA, European Medicines Agency; ESCAT, ESMO Scale for Clinical Actionability of Molecular Targets; FDA, Food and Drug Administration; MCBS, ESMO-Magnitude of Clinical Benefit Scale; mNSCLC, metastatic non-small-cell lung cancer; RT, radiotherapy. ^aESMO-MCBS v1.1111 was used to calculate scores for new therapies/indications approved by the EMA or FDA. The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms).^35bESCAT scores apply to alterations from genomic-driven analyses only.³⁶ These scores were defined by the ESMO CPG authors and validated by the ESMO Translational Research and Precision Medicine Working Group.³⁴